Physicians often rely on multiple sources of clinical information to evaluate pulmonary nodules for cancer. CyPath Lung provides real-time diagnostic insight that complements imaging and other clinical findings for earlier detection of malignancy.
cypathlung.com $BIAF
- bioAffinity Technologies reported second quarter 2026 financial results and continued strong commercial momentum for CyPath® Lung. CyPath® Lung test volume increased 216% year over year as physician adoption continued to grow. bit.ly/4hVySkc $BIAF
- Patients want answers they can understand. CyPath Lung provides additional diagnostic information to help physicians assess malignancy risk. This physician knows that a negative CyPath Lung test result eases a patient’s anxiety and provides reassurance about next steps. $BIAF
- Managing indeterminate pulmonary nodules takes more than one perspective. Hear an interventional pulmonologist, thoracic surgeon and medical oncologist discuss where #CyPathLung fits into patient evaluation. 🎙️Listen: bit.ly/4w4koSA $BIAF #lungcancer
- Our Veterans' health is a top priority. So proud to support NAVREF as we bring CyPath Lung to improve care for the men and women who served our country



